๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› USA
Clinical trial register · United States · industry-sponsored

Industry-sponsored studies with a US investigative site

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9112 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:16 UTC
9112
Studies in scope
industry-sponsored, all four open statuses
4950
Recruiting now
open to new participants
2202
Lead sponsors
across recruiting studies
Top states
California 5295 Florida 4397 Illinois 2479 Georgia 2346 Arizona 2231
Narrow the register
Recruitment status
Phase
Lead sponsor
AstraZeneca299 Novartis Pharmaceuticals202 Eli Lilly and Company190 Merck Sharp & Dohme LLC183 AbbVie172
State
California5295 Florida4397 Illinois2479 Georgia2346 Arizona2231
All 51 states
Target enrolment
to
9112 of 9112 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
NCT06392386Generalized Myasthenia Gravis
argenx
Phase 2/3
12
North Carolina, Texas, Virginia
2024-06-28
Active, closed
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
NCT06331312Polymyalgia Rheumatica
Novartis Pharmaceuticals
Phase 3
162
Arizona, California, Florida, Maryland, Michigan, New Hampshire, Ohio, Texas
2024-06-28
Recruiting
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Boehringer Ingelheim
Phase 1/2
768
California, Connecticut, Florida, Illinois, Indiana, Iowa, Massachusetts, Michigan
2024-06-28
Active, closed
A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)
NCT06455098Atrial Fibrillation
Biosense Webster, Inc.
Not applicable
353
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland
2024-06-28
By invitation
Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry
NCT06512324Major Depressive Disorder, MDD, Generalized Anxiety Disorder, GAD
Biomedical Discoveries and Neuroscientific Foundations LLC
Observational
5,000
California, Texas
2024-06-27
Recruiting
HPC Offered for PRESERVE Expansion
NCT07145411Bone Marrow Transplant (BMT)
Ossium Health, Inc.
Observational
10
Alabama, Michigan, Ohio, Tennessee
2024-06-27
Active, closed
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228Hidradenitis Suppurativa
AbbVie
Phase 3
1,400
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2024-06-27
Active, closed
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
NCT06447662Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Pfizer
Phase 1
64
Arkansas, California, Colorado, District of Columbia, Michigan, Missouri, North Carolina, Ohio
2024-06-27
Recruiting
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
NCT06452160Mesothelioma, Epithelioid Hemangioendothelioma(EHE), Solid Tumor
BridGene Biosciences Inc.
Phase 1
103
Texas
2024-06-27
Recruiting
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
NCT06207032Cancer
Tempus AI
Observational
500
Alabama, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky
2024-06-26
Recruiting
BiVACORยฎ Total Artificial Heart Early Feasibility Study
NCT06174103Heart Failure, Biventricular Failure
BiVACOR Inc.
Not applicable
5
Arizona, North Carolina, Ohio, Texas
2024-06-26
Active, closed
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Novo Nordisk A/S
Phase 3
10,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia
2024-06-25
Active, closed
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
NCT06496178Head and Neck Squamous Cell Carcinoma
Merus B.V.
Phase 3
621
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2024-06-25
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
California, Connecticut, District of Columbia, Illinois, Indiana, Maryland, Massachusetts, Minnesota
2024-06-25
Active, closed
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
NCT06425549Moderate to Severe Plaque Psoriasis
UCB Biopharma SRL
Phase 3
176
California, Indiana, South Carolina, Texas
2024-06-25
Active, closed
Validation of i-ROP DL to Detect More Than Mild ROP
NCT06109285Retinopathy of Prematurity, ROP
Siloam Vision
Not applicable
16
Oregon
2024-06-25
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587Generalized Myasthenia Gravis
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Arizona, Colorado, Connecticut, District of Columbia, Florida, Kansas, North Carolina, Ohio
2024-06-25
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC
Phase 3
1,530
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2024-06-24
Recruiting
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06307795Locally Advanced or Metastatic Solid Tumors
Avistone Biotechnology Co., Ltd.
Phase 1
63
California, Colorado, Florida, Michigan, New York, Texas, Virginia, Washington
2024-06-24
Active, closed
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
NCT06495164Breast Cancer, Malignant Neoplasm of Breast
Pfizer
Observational
1
New York
2024-06-24
Recruiting
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis
NCT06429176Cystic Fibrosis
SpliSense Ltd.
Phase 2
64
California, Colorado, Massachusetts
2024-06-24
Recruiting
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
NCT06548672Advanced Cancer, Metastatic Solid Tumor
Biocity Biopharmaceutics Co., Ltd.
Phase 1
148
Ohio
2024-06-24
Recruiting
Study Assessing Complete Wound Healing by Comparing Surgenexยฎ PelloGraft in Treating DFU and SanoGraftยฎ in Treating VLU to SOC
NCT06515093Diabetic Foot Ulcer, Venous Leg Ulcer
Surgenex
Not applicable
180
California, Oklahoma
2024-06-23
Recruiting
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
NCT07491172Cardiovascular, Metabolic Disease, Dyslipidemias, Lipid Disorder
CRISPR Therapeutics AG
Phase 1
90
Florida, New York, North Carolina, Oregon
2024-06-21
Recruiting
KiteLock 4% EDTA Lock Solution for the Prevention of Occlusions in Children With Intestinal Failure
NCT05879835Pediatric Intestinal Failure
SterileCare Inc.
Not applicable
124
Massachusetts, Nebraska, New York, North Carolina, Ohio, Texas, Washington
2024-06-21
Recruiting
Randomized Trial of UI-EWD vs. Conventional Endoscopic Therapy for Nonvariceal Upper Gastrointestinal Bleeding
NCT06188585Acute Gastrointestinal Bleeding
Medtronic - MITG
Not applicable
278
Connecticut, Illinois, Massachusetts, New Jersey, New York
2024-06-21
Recruiting
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
NCT06257693Prostate Adenocarcinoma
Alessa Therapeutics Inc.
Phase 1
45
California, Illinois, Louisiana, Maryland, Oregon, South Carolina, Virginia, Wisconsin
2024-06-21
Recruiting
Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)
NCT06445322Stargardt Disease, Stargardt Disease 1, Cone Rod Dystrophy, Juvenile Macular Degeneration
Ascidian Therapeutics, Inc
Observational
50
California, Florida, Maryland, Massachusetts, Michigan, Ohio, Texas
2024-06-20
Recruiting
Atrial Flutter Ablation in the iCMR
NCT05904548Atrial Flutter Typical
Imricor Medical Systems
Not applicable
91
Maryland, Virginia
2024-06-20
Recruiting
The Golazoยฎ Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
NCT06321575Peripheral Arterial Disease
Nipro Vascular Innovations Americas, Inc
Not applicable
159
Arizona, California, Florida, Georgia, Hawaii, Louisiana, Massachusetts, New Jersey
2024-06-20
Active, closed
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
NCT05897424Alpha 1-Antitrypsin Deficiency, Emphysema
Sanofi
Phase 2
185
Alabama, Arizona, California, Colorado, Connecticut, Florida, Indiana, Massachusetts
2024-06-20
Recruiting
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
NCT06455449Polymyositis, Dermatomyositis
AstraZeneca
Phase 3
240
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2024-06-20
Recruiting
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
NCT06428409Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
Merck Sharp & Dohme LLC
Phase 1/2
220
California, Colorado, District of Columbia, Florida, Georgia, New York, Texas, Virginia
2024-06-20
Recruiting
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
NCT06115135Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Oncotherapeutics
Phase 2
39
California, Nebraska
2024-06-20
Active, closed
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
NCT06462547Gene Mutations, Pseudoxanthoma Elasticum, Arterial Calcification, Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency
Inozyme Pharma
Phase 2
22
Minnesota, New Jersey
2024-06-19
Recruiting
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
NCT06471829Cushing's Disease
H. Lundbeck A/S
Phase 2
18
Michigan, Missouri
2024-06-19
Recruiting
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
NCT06501196Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia
BlossomHill Therapeutics
Phase 1
170
California, Florida, Illinois, New York, Ohio, Tennessee, Texas, Washington
2024-06-19
Recruiting
Evaluation of the Patellar LIFT System for Subjects With Patellofemoral Cartilage Degeneration
NCT06423300Patellofemoral Osteoarthritis
ZKR Orthopedics Inc
Not applicable
245
California, New York, Ohio, Oregon
2024-06-19
Recruiting
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
NCT06399419Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
Osel, Inc.
Phase 1
28
California
2024-06-19
Recruiting
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
NCT06389877Alpha 1-Antitrypsin Deficiency
Beam Therapeutics Inc.
Phase 1/2
106
Alabama, Massachusetts, South Carolina
2024-06-19
Active, closed
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129Large B-cell Lymphoma
Celgene
Phase 3
850
Alabama, Alaska, Arizona, California, Florida, Georgia, Illinois, Iowa
2024-06-19
Recruiting
Study of SGR-3515 In Participants With Advanced Solid Tumors.
NCT06463340Advanced Solid Tumor
Schrรถdinger, Inc.
Phase 1
52
Connecticut, Illinois, Michigan, New York, North Carolina, Ohio, Oklahoma, Tennessee
2024-06-18
Active, closed
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
NCT06399757Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma
Apollo Therapeutics Ltd
Phase 1/2
100
California, Florida, Michigan, North Carolina, South Carolina, Texas
2024-06-18
Active, closed
A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa
NCT06388200Retinitis Pigmentosa
Ocugen
Phase 3
140
Arizona, California, Florida, Pennsylvania, Tennessee, Texas, Wisconsin
2024-06-18
Recruiting
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273Large B-cell Lymphoma
Allogene Therapeutics
Phase 2
250
Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida, Georgia
2024-06-18
Recruiting
Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis
NCT06207370Babesiosis
60 Degrees Pharmaceuticals LLC
Phase 2
33
Massachusetts
2024-06-17
Active, closed
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
NCT06455059Hypochondroplasia
BioMarin Pharmaceutical
Phase 3
80
Delaware, District of Columbia, Illinois, Wisconsin
2024-06-17
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288Heart Failure
Boehringer Ingelheim
Phase 3
6,712
Alabama, California, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana
2024-06-17
Active, closed
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06223516Multiple Myeloma
AbbVie
Phase 1
60
Arizona, Florida, Michigan, Minnesota, North Carolina, Wisconsin
2024-06-17
By invitation
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent ฮฒ-Thalassemia Who Received EDIT-301
NCT06363760Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia, Hemoglobinopathies
Editas Medicine, Inc.
Observational
54
California, Colorado, Connecticut, Florida, Georgia, Minnesota, New York, North Carolina
2024-06-17
Recruiting
A Study of Radspherinยฎ in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
NCT06504147Peritoneal Carcinomatosis, Ovarian Cancer
Oncoinvent Solutions AS
Phase 2
114
Florida
2024-06-15
Active, closed
IBRX-042 In Participants With HPV-Associated Tumors
NCT05976828HPV-Related Carcinoma
ImmunityBio, Inc.
Phase 1
12
California, Texas
2024-06-14
Active, closed
Food Trial to Evaluate the Kinetics of the Medical Foods SBD111 and SBD121 Persistence in Healthy Adults
NCT06614166Product Persistence in GI Tract, Kinetics, Rheumatoid Arthritis (RA), Bone Density
Solarea Bio, Inc
Not applicable
40
Massachusetts
2024-06-14
Recruiting
Cross-sectional and Prospective Study to Characterize Early-onset Presbycusis
NCT06354010Sensorineural Hearing Loss, Bilateral
Sensorion
Observational
100
Florida
2024-06-14
Active, closed
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
NCT06334133Diabetes Mellitus, Type 1
vTv Therapeutics
Phase 3
150
Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho, Indiana
2024-06-14
Recruiting
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
NCT06389136Atopic Dermatitis
AbbVie
Phase 3
200
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2024-06-14
Recruiting
Study of APR-1051 in Patients With Advanced Solid Tumors
NCT06260514Advanced Solid Tumor
Aprea Therapeutics
Phase 1
90
Ohio, Texas, Virginia
2024-06-13
Recruiting
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
NCT06557265Lupus Nephritis, Primary Membranous Nephropathy
Nkarta, Inc.
Phase 1/2
120
Arkansas, California, Florida, Georgia, Illinois, Louisiana, Massachusetts, Michigan
2024-06-13
Recruiting
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT06095128Ulcerative Colitis
Takeda
Phase 4
60
Alabama, Arizona, California, Florida, Georgia, Illinois, Kansas, Kentucky
2024-06-12
Recruiting
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505Ovarian Cancer, Non-small Cell Lung Cancer
Tubulis GmbH
Phase 1/2
250
Alabama, Connecticut, Georgia, Kentucky, Massachusetts, New Jersey, New York, Ohio
2024-06-12
Recruiting
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
NCT06382168Leukemia, Myeloid, Acute
Delta-Fly Pharma, Inc.
Phase 1/2
39
California, North Carolina, Vermont, Virginia
2024-06-12
Recruiting
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06239194Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
ModeX Therapeutics, An OPKO Health Company
Phase 1/2
285
Colorado, Florida, Massachusetts, Tennessee, Texas
2024-06-12
Recruiting
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
NCT06063850Mesial Temporal Lobe Epilepsy
UniQure Biopharma B.V.
Phase 1/2
12
Alabama, Arizona, California, Florida, Kansas, Maryland, Massachusetts, Michigan
2024-06-12
Active, closed
A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
NCT06480240Advanced Solid Tumor
OBI Pharma, Inc
Phase 1/2
117
California, Michigan, Texas, Virginia
2024-06-12
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
NCT06305754Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
550
California, Florida, Georgia, Michigan, Missouri, New Jersey, New York, North Dakota
2024-06-11
Recruiting
Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
NCT06467344Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1
Ascidian Therapeutics, Inc
Phase 1/2
15
California, Florida, Maryland, Massachusetts, Michigan, Ohio, Oregon, Texas
2024-06-11
Recruiting
Study of ALTO-101 in Patients With Schizophrenia
NCT06502964Schizophrenia, Cognitive Impairment
Alto Neuroscience
Phase 2
82
California, Florida, Georgia, Illinois, Maryland, Massachusetts, New York
2024-06-11
Active, closed
RHAยฎ Redensity With New Anesthetic Agent Perioral Rhytids (PAS)
NCT06378086Pain, Aging
Teoxane SA
Not applicable
20
Alabama, New York
2024-06-11
Recruiting
Transdermal Compress IDE Study
NCT06134167Prosthesis and Implants
Balmoral Medical company
Not applicable
100
California, Colorado, Illinois, Maryland, New York, Ohio, Pennsylvania
2024-06-11
Recruiting
Home Reported Outcomes in PNH
NCT06411626Paroxysmal Nocturnal Hemoglobinuria
Novartis Pharmaceuticals
Observational
128
New Jersey
2024-06-11
Recruiting
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
NCT06190886Advanced Cancer, Solid Tumor, Metastatic Cancer
Proviva Therapeutics, Inc.
Phase 1
26
California, Florida, Nebraska
2024-06-11
Recruiting
A Multi-center, National, Open-label, Prospective Study to Evaluate the Performance of the V-Lapโ„ข System
NCT06147336Heart Failure
Vectorious Medical Technologies Ltd.
Not applicable
10
Massachusetts
2024-06-11
Recruiting
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
NCT06285643Parkinson Disease
AskBio Inc
Phase 2
127
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-06-11
Recruiting
Clinical Outcomes Related to Treatment of Distal Symmetric Polyneuropathy Using Semiconductor Embedded Therapeutic Socks
NCT06452914Diabetic Neuropathy
Endocrine Research Solutions
Not applicable
80
Georgia
2024-06-11
Recruiting
VenusP-Valve Pivotal Study (PROTEUS STUDY)
NCT06010563Pulmonary Regurgitation
Venus MedTech (HangZhou) Inc.
Not applicable
60
California
2024-06-11
Active, closed
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
NCT06472076Lung Cancer, Non-Small Cell
GlaxoSmithKline
Phase 3
88
Florida, Hawaii, Kentucky, Nebraska, Tennessee, Texas, Washington
2024-06-10
Recruiting
VasoStar Vibrational Guidewire System to Facilitate Crossing Coronary Artery Chronic Total Occlusions
NCT06193954Chronic Total Occlusion of Coronary Artery, Chronic Angina
VasoStar, LLC
Not applicable
10
Georgia, Ohio
2024-06-10
Active, closed
A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy
NCT06414603Heart Transplant Failure and Rejection
Natera, Inc.
Not applicable
250
California, Colorado, Florida, Kansas, Massachusetts, Michigan, New York, North Carolina
2024-06-10
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
Merck Sharp & Dohme LLC
Phase 3
851
Arkansas, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Michigan
2024-06-10
Recruiting
MagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion
NCT05037968Degenerative Disc Disease, Spine Fusion, Leg Pain and/or Back Pain
Kuros Biosurgery AG
Not applicable
100
Connecticut, Illinois, Maryland, Michigan, North Carolina, Ohio, Utah, Virginia
2024-06-10
Recruiting
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
NCT06311682Atopic Dermatitis
LEO Pharma
Phase 3
195
Alabama, Arkansas, California, Florida, Georgia, Michigan, Oklahoma, Oregon
2024-06-10
Active, closed
A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
NCT05767736Multiple Sclerosis
Biogen
Observational
10,500
Massachusetts
2024-06-08
Active, closed
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT06082167Head and Neck Squamous Cell Carcinoma
Exelixis
Phase 2/3
600
California, Florida, Georgia, Illinois, Iowa, Missouri, New Hampshire, New Jersey
2024-06-07
Recruiting
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
NCT06401421Breast Cancer
Exact Sciences Corporation
Observational
1,800
Alaska, California, Colorado, Florida, Illinois, Indiana, Kansas, Kentucky
2024-06-07
Active, closed
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991Multiple Myeloma
Janssen Research & Development, LLC
Phase 1
108
Arizona, Colorado, Florida, Georgia, Indiana, Ohio, Texas
2024-06-07
Active, closed
NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers
NCT06402565Diabetic Foot Ulcer
NOxy Health Products, LLC
Phase 1
40
Arizona, Florida, Massachusetts, Ohio, Texas
2024-06-06
Recruiting
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
NCT06056297Neutropenia
X4 Pharmaceuticals
Phase 3
176
Arizona, California, Florida, Georgia, Iowa, Massachusetts, Michigan, Missouri
2024-06-06
Active, closed
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249Systemic Lupus Erythematosus
GlaxoSmithKline
Phase 4
303
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Michigan
2024-06-06
Recruiting
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
NCT06332755Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma
LG Chem
Phase 1
76
Virginia
2024-06-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
Merck Sharp & Dohme LLC
Phase 3
1,200
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2024-06-05
Recruiting
A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
NCT06277219Advanced Solid Tumor
Latticon Antibody Therapeutics, Inc
Phase 1/2
150
Florida, Utah
2024-06-05
Recruiting
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT06112314Advanced Melanoma
Immunocore Ltd
Phase 3
680
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2024-06-05
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Amgen
Phase 3
563
Alabama, California, Connecticut, Georgia, Illinois, Indiana, Louisiana, Massachusetts
2024-06-05
Recruiting
Prospective Clinical Assessment Study in Children With Hypochondroplasia
NCT06410976Hypochondroplasia
QED Therapeutics, a BridgeBio company
Observational
150
California, Colorado, District of Columbia, Maryland, Missouri, Ohio, Tennessee, Wisconsin
2024-06-05
Active, closed
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
NCT06097832Light Chain (AL) Amyloidosis
Nexcella Inc.
Phase 1/2
45
California, Georgia, Kansas, Massachusetts, Michigan, Minnesota, Missouri, New York
2024-06-05
Recruiting
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
NCT06270316Fabry Disease
UniQure Biopharma B.V.
Phase 1/2
12
Alabama, Georgia, Illinois, Minnesota, New York, Pennsylvania, Utah, Virginia
2024-06-05
Recruiting
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
NCT06459973Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
252
Colorado, Connecticut, Florida, Kentucky, Missouri, Nevada, New Mexico, Oklahoma
2024-06-04
Active, closed
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06507306Solid Tumor, Adult
Kumquat Biosciences Inc.
Phase 1
92
Colorado, Florida, Michigan, New York, Ohio, Tennessee, Texas, Virginia
2024-06-03
Active, closed
Using a Novel Skin Tag Removal Device
NCT06463613Achrochordon
UK Innovations GP LTD
Not applicable
200
California
2024-06-03
Recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277Obesity, Weight Gain
Eli Lilly and Company
Phase 3
300
California, Delaware, Idaho, Illinois, Indiana, New York, Texas, Utah
2024-06-03
Rows per page Showing 5001–5100 of 9112
Previous 49 50 51 52 53 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-usa?page=51

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
→

Browse trials by condition

Advanced Solid Tumor (143) Breast Cancer (139) Obesity (123) Multiple Myeloma (109) Advanced Solid Tumors (89) Colorectal Cancer (83) Solid Tumor (81) Overweight (77) Ovarian Cancer (74) Healthy (73) Prostate Cancer (73) Heart Failure (72) Non-Small Cell Lung Cancer (70) Cancer (65) Melanoma (63)
→

Browse trials by state

California (5295) Florida (4397) Illinois (2479) Georgia (2346) Arizona (2231) New York (2126) Colorado (2066) Texas (1969) Massachusetts (1836) Michigan (1481) Alabama (1288) Connecticut (1274) Maryland (1267) Ohio (1252) Indiana (1114)
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.